thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
=== EC 2.8.3: CoA-transferases === EC 2.8.3.1: propionate CoA-transferase EC 2.8.3.2: oxalate CoA-transferase EC 2.8.3.3: malonate CoA-transferase EC 2.8.3.4: deleted EC 2.8.3.5: 3-oxoacid CoA-transferase EC 2.8.3.6: 3-oxoadipate CoA-transferase EC 2.8.3.7: The activity is due to two enzymes, EC 2.8.3.22, succinyl-CoA—L-malate CoA-transferase and EC 2.8.3.20, succinyl-CoA—Dcitramalate CoA-transferase EC 2.8.3.8: acetate CoA-transferase EC 2.8.3.9: butyrate—acetoacetate CoA-transferase EC 2.8.3.10: citrate CoA-transferase EC 2.8.3.11: citramalate CoA-transferase EC 2.8.3.12: glutaconate CoA-transferase EC 2.8.3.13: succinate—hydroxymethylglutarate CoA-transferase EC 2.8.3.14: 5-hydroxypentanoate CoA-transferase EC 2.8.3.15: succinyl-CoA:(R)-benzylsuccinate CoA-transferase EC 2.8.3.16: formyl-CoA transferase EC 2.8.3.17: cinnamoyl-CoA:phenyllactate CoA-transferase EC 2.8.3.18: succinyl-CoA:acetate CoA-transferase EC 2.8.3.19: CoA:oxalate CoA-transferase EC 2.8.3.20: succinyl-CoA—D-citramalate CoA-transferase EC 2.8.3.21: L-carnitine CoA-transferase EC 2.8.3.22: succinyl-CoA—L-malate CoA-transferase EC 2.8.3.23: caffeate CoA-transferase EC 2.8.3.24: (''R'')-2-hydroxy-4-methylpentanoate CoA-transferase EC 2.8.3.25: bile acid CoA-transferase EC 2.8.3.26: succinyl-CoA:mesaconate CoA transferase
Surfactant protein D, also known as SP-D, is a lung surfactant protein part of the collagenous family of lectins called collectin. In humans, SP-D is encoded by the SFTPD gene and is part of the innate immune system. Each SP-D subunit is composed of an N-terminal domain, a collagenous region, a nucleating neck region, and a C-terminal lectin domain. Three of these subunits assemble to form a homotrimer, which further assemble into a tetrameric complex.
Zverev opened his 2019 season with a fourth round appearance at the 2019 Australian Open, defeating Jérémy Chardy in five sets in the second round before losing to Milos Raonic in straight sets. Zverev next played at the Mexican Open and finished runner-up to Nick Kyrgios. Following this tournament, he did not win more than one match at any of his next six events, a streak that ended with two match wins at the Madrid Open. Nonetheless, Zverev finished the clay court season strong. The week before the French Open, he won his only title of the year at the Geneva Open, defeating Nicolás Jarry in the final after saving two match points in the third set tiebreak. He then went on to defeat No. 12 Fabio Fognini and reach his second consecutive quarterfinal at the French Open, where he lost to Novak Djokovic. Zverev did not follow through on that success into the grass court season, where his best result was a quarterfinal at the Halle Open. He was upset in the first round at both the Stuttgart Open and Wimbledon, the latter of which to qualifier Jiří Veselý. Zverev attributed his early season struggles to being distracted by a legal dispute with his former agent Patricio Apey, with whom he had split from in the offseason. Zverev began to turn his season around following Wimbledon. He reached the semifinals of the German Open and the quarterfinals at the Canadian Open. He then reached the last 16 at the US Open for the first time, where he lost to seed No. 20 Diego Schwartzman to continue his lack of success at the major tournaments.
The Ural Cossack Host was formed from the Ural Cossacks, who had settled along the Ural River. Their alternative name, Yaik Cossacks, comes from the river's former name, changed by the government after Pugachev's Rebellion of 1773–1775. The Ural Cossacks spoke Russian, and identified as having primarily Russian ancestry, but also incorporated many Tatars into their ranks. In 1577, twenty years after Moscow had conquered the Volga from Kazan to Astrakhan, the government sent troops to disperse pirates and raiders along the Volga. Among them was Yermak Timofeyevich. Some escaped to flee southeast to the Ural River, where they joined the Yaik Cossacks. In 1580, they captured Saraichik. By 1591, they were fighting on behalf of the government in Moscow. Over the next century, they were officially recognized by the imperial government.
This enzyme belongs to the family of isomerases, specifically cis-trans isomerases. The systematic name of this enzyme class is 4-maleylacetoacetate cis-trans-isomerase. 4-Maleylacetoacetate isomerase is an enzyme involved in the degradation of L-phenylalanine. It is encoded by the gene glutathione S-transferase zeta 1, or GSTZ1. This enzyme catalyzes the conversion of 4-maleylacetoacetate to 4-fumarylacetoacetate. 4-Maleylacetoacetate isomerase belongs to the zeta class of the glutathione S-transferase (GST) superfamily.
Sources: en.wikipedia.org
== Statistical physics and thermodynamics == Non-equilibrium thermodynamics is a branch of physics that studies the dynamics of statistical ensembles of molecules via unstable states. Being "stuck" in a thermodynamic trough without being at the lowest energy state is known as having kinetic stability or being kinetically persistent. The particular motion or kinetics of the atoms involved has resulted in getting stuck, despite there being preferable (lower-energy) alternatives.
== Pathology == VIP is overproduced in VIPoma. In addition to VIPoma, VIP has a role in osteoarthritis (OA). While there is existing conflict in whether down-regulation or up-regulation of VIP contributes to OA, VIP has been shown to prevent cartilage damage in animals.
== Side effects == The most common side effects include constipation, nausea and drowsiness. Others include coughing up blood from the lungs, skin rashes, dizziness, sedation, shortness of breath, hypersensitivity reaction, fainting (syncope or near syncope), confusion, loss of short-term memory, changes in blood, allergic reactions, euphoria, dysphoria, abdominal pain, itchiness, easy bruising, bleeding gums, vivid dreams, dry mouth and addiction. Genetic differences between people cause differing rates of metabolism of codeine to morphine. In about 5 percent of people this may happen particularly fast, causing morphine to be passed through breast milk in amounts that may cause fatal respiratory depression in a breastfed baby.
== External links == "Loncastuximab tesirine-lpyl". NCI Drug Dictionary. National Cancer Institute. "Loncastuximab tesirine-lpyl". National Cancer Institute. 21 May 2021. Clinical trial number NCT03589469 for "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)" at ClinicalTrials.gov
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.